Spots Global Cancer Trial Database for Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
Official Title: Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
Study ID: NCT05518838
Interventions
Study Description
Brief Summary: To provide OKN-007 for compassionate use in patients with diffuse midline glioma, H3 K27-altered (DMG), including diffuse intrinsic pontine glioma (DIPG), pediatric and young adult patients with high-grade diffuse midline glioma will be treated under this Intermediate-sized expanded access treatment protocol.
Detailed Description:
Keywords
Eligibility
Minimum Age: 13 Months
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Arkansas Children's Research Institute, Little Rock, Arkansas, United States
Nicklaus Children's Hospital, Miami, Florida, United States
Arnold Palmer Hospital for Children, Orlando, Florida, United States
Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States
Children's Hospital and Medical Center, Omaha, Nebraska, United States
Prisma Health Midlands Pediatric Hematology/Oncology, Columbia, South Carolina, United States
Children's Health, Dallas, Texas, United States
Children's Hospital of The King's Daughters, Norfolk, Virginia, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
